Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~The subject must have:~* Her most recent surgical and - if available - histological diagnosis of pelvic endometriosis up to 10 years before screening.~* Moderate to severe endometriosis-associated pain during the screening period.~* Regular menstrual cycles.~* BMI ≥ 18 kg/m2 at the screening visit. -~Exclusion Criteria:~The subject will be excluded if she:~* Is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.~* Is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of entry into the screening period.~* Has had a surgical history of any major abdominal surgery within 6 months or any interventional surgery for endometriosis performed within a period of 2 months before screening.~* Did not respond to prior treatment with GnRH agonists or GnRH antagonists for endometriosis.~* Has a history of, or known, osteoporosis or other metabolic bone disease.~* Has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic or other chronic therapy which would interfere with the assessment of endometriosis-associated pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Linzagolix 75 mg (Type: EXPERIMENTAL): None
- Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).